Inflammatory Bowel Disease

  • Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease
    Aaron Brzezinski, MD, George B. Rankin, MD, Douglas L. Seidner, MD and Bret A. Lashner, MD, MPH
    Cleveland Clinic Journal of Medicine September 1995, 62 (5) 317-323;

    Sulfasalazine, a 5-ASA agent, is the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease. Newer delayed-release formulations can also be appropriate first-line agents.

  • Management of inflammatory bowel disease: 30 years of observation
    William M. Michener, MD, Maureen Caulfield, MD, Robert Wyllie, MD and Richard G. Farmer, MD
    Cleveland Clinic Journal of Medicine November 1990, 57 (8) 685-691;

    Data based on three decades of direct patient care indicate that patients with inflammatory bowel disease have specific treatment options and can count on long, productive lives.